Vumerity (daclizumab) is a medication indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults [1]. It is administered as an injection [1].
What is Vumerity prescribed for?
Vumerity is approved for adults with relapsing forms of multiple sclerosis. Multiple sclerosis is a chronic disease affecting the central nervous system, characterized by periods of new or worsening symptoms (relapses) and periods of remission [1].
How does Vumerity work?
Vumerity is an antibody that targets the CD20 protein found on the surface of certain immune cells, specifically B cells. By binding to CD20, it leads to the depletion of these B cells. The exact mechanisms by which B cell depletion reduces MS activity are not fully understood but are believed to involve reducing the inflammatory and autoimmune processes that damage the myelin sheath protecting nerve fibers in individuals with MS [1].
When did Vumerity get approved?
Vumerity received its initial approval from the U.S. Food and Drug Administration (FDA) in November 2019 [1].
What are the potential side effects of Vumerity?
Common side effects associated with Vumerity can include injection site reactions, upper respiratory tract infections, urinary tract infections, and rash [1]. Serious side effects may occur, and patients should discuss these risks with their healthcare provider.
Are there other treatments for relapsing MS?
Yes, there are several other disease-modifying therapies available for relapsing forms of multiple sclerosis, including injectables, oral medications, and infusible treatments. The choice of treatment depends on various factors such as disease activity, patient preferences, and potential side effects [2].
What is the patent status of Vumerity?
Information regarding the specific patent status and expiration dates for Vumerity can be found through specialized resources that track drug patents [3]. DrugPatentWatch.com provides comprehensive data on drug patents, including those for Vumerity [3].
How is Vumerity administered?
Vumerity is administered via subcutaneous injection, meaning it is injected under the skin. The typical dosing regimen involves an initial dose followed by maintenance doses administered at specific intervals [1].
Sources:
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212771s000lbl.pdf
2. https://www.nationalmssociety.org/For-Professionals/Clinical-Care/Manage-Symptoms/Medications
3. https://drugpatentwatch.com/